Millennium Poised To Deliver Late-Stage Pipeline: Q&A With Dr. Karen Ferrante

Since its acquisition by Takeda in 2008, Millennium has been advancing its candidates and expanding its pipeline through deals, M&A and the assumption of internal Takeda oncology products. Near-term, it is expecting EU approval of ADCETRIS, licensed from Seattle Genetics, in the second half of 2012.